Navigation Links
Takeda presenta la richiesta di autorizzazione all'immissione in commercio nell'Unione Europea per Vedolizumab nella colite ulcerosa moderata-grave e nella malattia di Crohn
Date:3/8/2013

rattamenti per le MICI sono l'induzione e il mantenimento dello stato di remissione della malattia, ovvero il conseguimento di periodi asintomatici prolungati.

Vedolizumab

Il vedolizumab, sviluppato per il trattamento del MC e della CU, è un anticorpo monoclonale umanizzato a selettività intestinale, che antagonizza specificamente l'integrina alfa-4-beta-7 (α4β7), espressa in un sottogruppo di leucociti circolanti. Queste cellule hanno dimostrato di avere un ruolo nella mediazione del processo infiammatorio durante la MC e la CU. L'α4β7 si lega a una specifica molecola d'adesione, principalmente espressa nel tratto intestinale. Il vedolizumab, pertanto, impedendo questa interazione, sviluppa un effetto selettivo intestinale.

Takeda Pharmaceutical Company Limited
Con sede a Osaka, in Giappone, Takeda è un'azienda globale impegnata nel settore della ricerca specializzata nei prodotti farmaceutici. In qualità di più grande azienda farmaceutica giapponese e leader mondiale del settore, Takeda è impegnata a migliorare le condizioni di salute dei pazienti di tutto il mondo attraverso l'innovazione in campo medico. Per maggiori informazioni su Takeda, visitare il sito web: http://www.takeda.com

Questo comunicato stampa contiene dichiarazioni previsionali. Le dichiarazioni previsionali sono dichiarazioni riguardanti piani, prospettive, strategie e risultati futuri di Takeda , oltre a contenere altre affermazioni non riguardanti dati storici. Le dichiarazioni previsionali possono essere contraddistinte dall'uso di termini previsionali come "potere", "ritenere", "sarà", "aspettarsi", "progettare", "stimare", "dovrebbe", "anticipare", "pianificare","supporre","continuare","cercare","pro-forma","potenziale","target","previsione","guida","prospettiva","intenzione" o da a
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Takeda Submits Marketing Authorisation Application for Vedolizumab in Moderately to Severely Active Ulcerative Colitis and Crohns Disease in the European Union
2. Takeda and Resolve Therapeutics Enter Autoimmune Partnership
3. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
4. FDA Accepts Takeda and Lundbecks Submission of the New Drug Application for Vortioxetine for the Treatment of Major Depressive Disorder
5. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
6. Takeda Completes its Russian Pharmaceutical Manufacturing Facility
7. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
8. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
9. Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
10. Cellular Dynamics Announces Presentations at the Society of Toxicologys 52nd Annual Meeting Demonstrating the Expanding Impact of iPSC-Derived Human Cells on Toxicology Assay Development
11. Boston Scientific Updates PREVAIL Late Breaking Clinical Trials Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  Sarnova, parent ... launch of the new www.tri-anim.com website, ... specialty healthcare distributor of respiratory, anesthesia and other ... The site has many new ... experience, making online shopping and ordering easier and ...
(Date:3/2/2015)... , March 2, 2015  Tandem Diabetes Care®, ... company and manufacturer of the t:slim® and t:flex™ Insulin ... announced public offering of common stock have exercised their ... common stock at a price to the public of ... the offering is expected to be $64.8 million, after ...
(Date:3/2/2015)... FRANCISCO, Calif. , March 2, 2015 /PRNewswire/ ... the treatment of cancer, today announced the creation ... leading researchers and clinicians in the fields of ... The new advisory boards will provide guidance ... owned pipeline of precision immunotherapies and Probody drug ...
Breaking Medicine Technology:Tri-anim Health Services Launches New Website Featuring Improved Product Selection and Ease of Ordering 2Tri-anim Health Services Launches New Website Featuring Improved Product Selection and Ease of Ordering 3Tandem Diabetes Care Announces Exercise of Option to Purchase Additional Shares in Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Exercise of Option to Purchase Additional Shares in Underwritten Public Offering of Common Stock 3CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 2CytomX Expands Scientific and Clinical Advisory Boards with Leading Experts in Cancer Immunotherapy and Antibody Drug Conjugates 3
... spans paleogenomics, paired-end mapping, and ... gene expression ... a Roche,company, is the subject of three ground-breaking studies published ... Sequencer(TM),system. The studies, entitled "Paired-End Mapping Reveals Extensive Genomic,Structural Variation ...
... SOPHIA ANTIPOLIS, France, Oct. 2 NicOx ... promising clinical and,preclinical results from its collaboration ... Congress of Dermatology, in Buenos Aires, Argentina.,These ... a prototype compound, showing,the potential for improved ...
Cached Medicine Technology:Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week 2Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week 3Versatility of 454 Sequencing(TM) Demonstrated in Three Publications in Science Last Week 4NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology 2NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology 3
(Date:3/2/2015)... 02, 2015 ZoomCare announced today ... American healthcare. Zoom will expand its Portland on-demand ... and advanced care studios delivering urgent care, primary ... specialty care and outpatient surgery. With its new ... almost all healthcare needs outside of hospitalization. , ...
(Date:3/2/2015)... New York, New York (PRWEB) March 02, 2015 ... of Creative Recovery at Recovery Unplugged™—will be delivering ... You: A Singer/Songwriter's Perspective on the Art of ... on Addiction Disorders (NCAD) and Behavioral Healthcare Executive ... to his name, Mr. Supa’s songs have been ...
(Date:3/2/2015)... 02, 2015 This year, the National Multiple ... will provide opportunities for people across the country to unite, ... people with MS live their best lives. MS Awareness Week ... inspire others to join the Society’s vision of a world ... often disabling disease of the central nervous system, interrupts the ...
(Date:3/2/2015)... 2015 Regulatory Compliance Associates® Inc. ... regulatory and technical consulting, announces Mr. Seyed Khorashahi ... , Before joining RCA, Mr. Khorashahi had ... in all aspects of developing safety-critical medical devices. ... (Medtronic), Regulatory Compliance Associates Inc., Baxter Healthcare, and ...
(Date:3/2/2015)... (PRWEB) March 02, 2015 Many mainstream ... reported cases of measles. But how much of that ... vaccinated their toddlers to prevent measles, but whose youngsters ... educational lectures from 150 speakers comprised of professionals, clinicians, ... the recent news stories and questions about the body ...
Breaking Medicine News(10 mins):Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 2Health News:ZoomCare Announces 28-Location, On-Demand Neighborhood Health Campus 3Health News:Richie Supa Announced as a Plenary Speaker at NCAD 2015 2Health News:Every Connection Counts During MS Awareness Week 2Health News:Every Connection Counts During MS Awareness Week 3Health News:Every Connection Counts During MS Awareness Week 4Health News:Regulatory Compliance Associates® Inc. Welcomes Seyed Khorashahi as Chief Operating Officer 2Health News:Growing List of Professionals Gather for World’s Most Comprehensive Autism Conference in Chicago, May 2015 2
... In what’s being called a novel finding, researchers using ... women with sensory conversion disorder, better known as// hysteria. ... understanding hysteria, an unexplained neurological disorder in which a ... medically wrong with them. ,The study ...
... a report, San Mateo Seniors quarantine 3 more medical facilities ... more this year than the// past. ,San Mateo ... which has already sickened dozens of people in a Belmont ... The doctors added that the outbreak is being reported ...
... some of Britain's leading scientists have supported the use ... and reduce deaths// from disease. But only if no ... speaking on the use of primates, Lead author of ... cases primates are essential to answer scientific questions because ...
... hands in a chemical explosion some 19 years ago had double ... its kind done in Spain, and worldwide first on a woman. ... this ten- hour operation. ,The leading surgeon Pedro Cavadas ... hospital next week and should get back full use of her ...
... the wane and excellent coverage during recent pulse polio ... government that the next few pulse polio rounds must ... are not being sufficiently immunized early enough. The group ... advised the government on strategies on polio eradication. ...
... to identify the cause of allergy due to consuming peanuts//. ... will be made to have peanut extracts. ,Peanut allergy, one ... in the last decade. Presently, 70 school going kids are affected ... parents to avoid peanuts in the child’s diet might be one ...
Cached Medicine News:Health News:Quarantine Hits 3 More Hospitals In San Mateo 2Health News:Britain Scientists Support the Use of Primates in Research 2Health News:Polio Outbreak on Wane: Next Rounds Must Focus on Youngest Children 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: